China ap­proves do­mes­tic Ebola vac­cine

BioSpectrum (Asia) - - Regulatory News -

The mil­i­tary-backed Bio­engi­neer­ing In­sti­tute of the Chi­nese Academy of Mil­i­tary Med­i­cal Sciences and pri­vate drug maker Cansino Bi­o­log­ics Inc., of Tian­jin have co-de­vel­oped a vac­cine for the deadly Ebola virus. Af­ter get­ting ap­proval from CFDA, China is now the third coun­try in the world, af­ter the US and Rus­sia, with an ap­proved vac­cine. The vac­cine, named re­com­bi­nant Ebola virus dis­ease vac­cine (Ade­n­ovirus type 5 vec­tor), is a re­com­bi­nant repli­ca­tion de­fec­tive hu­man Ad5 vec­tor-based vac­cine ex­press­ing Ebola virus gly­co­pro­tein, which can stim­u­late im­mu­nity against the Ebola virus in both hu­man cells and bod­ily flu­ids. CFDA has high­lighted in the an­nounce­ment that the newly ap­proved vac­cine is su­pe­rior to the cur­rently avail­able vac­cines in terms of the sta­bil­ity. The vac­cine is based on the 2014 mu­tant gene type and in the form of freeze-dried pow­der, which can re­main sta­ble for at least two weeks in tem­per­a­tures of up to 37 de­grees Cel­sius.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.